Header Logo

Connection

CRISTIAN COARFA to Cell Line, Tumor

Back to Details
This is a "connection" page, showing publications CRISTIAN COARFA has written about Cell Line, Tumor.
CRISTIAN COARFA
Connection Strength
1.022
Cell Line, Tumor
  1. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene. 2016 05 05; 35(18):2345-56.
    View in: PubMed
    Score: 0.044
  2. A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res. 2009 Feb; 19(2):167-77.
    View in: PubMed
    Score: 0.027
  3. SOD1 is a synthetic-lethal target in PPM1D-mutant leukemia cells. Elife. 2024 Jun 18; 12.
    View in: PubMed
    Score: 0.020
  4. Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer. Cancer Res. 2024 01 16; 84(2):291-304.
    View in: PubMed
    Score: 0.019
  5. TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2023 05 16; 120(20):e2218229120.
    View in: PubMed
    Score: 0.019
  6. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023 06; 128(11):2013-2024.
    View in: PubMed
    Score: 0.018
  7. PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. J Clin Invest. 2023 02 01; 133(3).
    View in: PubMed
    Score: 0.018
  8. LncRNA PVT-1 promotes osteosarcoma cancer stem-like properties through direct interaction with TRIM28 and TSC2 ubiquitination. Oncogene. 2022 Dec; 41(50):5373-5384.
    View in: PubMed
    Score: 0.018
  9. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nat Commun. 2022 06 28; 13(1):3728.
    View in: PubMed
    Score: 0.017
  10. ?Np63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun. 2022 02 01; 13(1):614.
    View in: PubMed
    Score: 0.017
  11. miR-181a Promotes Multiple Protumorigenic Functions by Targeting TGF?R3. J Invest Dermatol. 2022 07; 142(7):1956-1965.e2.
    View in: PubMed
    Score: 0.017
  12. Inhibition of GATA2 in prostate cancer by a clinically available small molecule. Endocr Relat Cancer. 2021 11 24; 29(1):15-31.
    View in: PubMed
    Score: 0.017
  13. CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming. Adv Sci (Weinh). 2021 10; 8(19):e2005047.
    View in: PubMed
    Score: 0.016
  14. A Wnt-Independent LGR4-EGFR Signaling Axis in Cancer Metastasis. Cancer Res. 2021 09 01; 81(17):4441-4454.
    View in: PubMed
    Score: 0.016
  15. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.
    View in: PubMed
    Score: 0.016
  16. Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells. Sci Rep. 2021 05 17; 11(1):10461.
    View in: PubMed
    Score: 0.016
  17. Isoform-specific Activities of Androgen Receptor and its Splice Variants in Prostate Cancer Cells. Endocrinology. 2021 03 01; 162(3).
    View in: PubMed
    Score: 0.016
  18. Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells. Sci Rep. 2021 01 14; 11(1):1393.
    View in: PubMed
    Score: 0.016
  19. p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma. Oncogene. 2021 02; 40(6):1176-1190.
    View in: PubMed
    Score: 0.016
  20. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
    View in: PubMed
    Score: 0.016
  21. Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nat Commun. 2020 10 14; 11(1):5156.
    View in: PubMed
    Score: 0.015
  22. An actin-WHAMM interaction linking SETD2 and autophagy. Biochem Biophys Res Commun. 2021 06 18; 558:202-208.
    View in: PubMed
    Score: 0.015
  23. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP. J Med Chem. 2020 05 14; 63(9):4716-4731.
    View in: PubMed
    Score: 0.015
  24. Mechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 04 09; 135(15):1255-1269.
    View in: PubMed
    Score: 0.015
  25. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors. Sci Rep. 2020 02 18; 10(1):2851.
    View in: PubMed
    Score: 0.015
  26. Long noncoding RNA BHLHE40-AS1 promotes early breast cancer progression through modulating IL-6/STAT3 signaling. J Cell Biochem. 2020 07; 121(7):3465-3478.
    View in: PubMed
    Score: 0.015
  27. MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin. Sci Rep. 2019 12 13; 9(1):19089.
    View in: PubMed
    Score: 0.015
  28. Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene. 2020 10; 39(40):6265-6285.
    View in: PubMed
    Score: 0.014
  29. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019 07; 20(7):835-851.
    View in: PubMed
    Score: 0.014
  30. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 07 04; 134(1):59-73.
    View in: PubMed
    Score: 0.014
  31. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer. 2019 07 15; 125(14):2409-2422.
    View in: PubMed
    Score: 0.014
  32. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4.
    View in: PubMed
    Score: 0.014
  33. Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab. 2019 01; 1(1):70-85.
    View in: PubMed
    Score: 0.014
  34. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene. 2019 02; 38(7):1121-1135.
    View in: PubMed
    Score: 0.013
  35. Steroid Receptor Coactivator-2 Controls the Pentose Phosphate Pathway through RPIA in Human Endometrial Cancer Cells. Sci Rep. 2018 09 03; 8(1):13134.
    View in: PubMed
    Score: 0.013
  36. Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer. Cancer Res. 2018 08 15; 78(16):4524-4532.
    View in: PubMed
    Score: 0.013
  37. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 2018 04; 556(7700):249-254.
    View in: PubMed
    Score: 0.013
  38. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018 04 03; 23(1):194-212.e6.
    View in: PubMed
    Score: 0.013
  39. GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. Endocr Relat Cancer. 2018 04; 25(4):453-469.
    View in: PubMed
    Score: 0.013
  40. ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells. Invest Ophthalmol Vis Sci. 2018 01 01; 59(1):132-143.
    View in: PubMed
    Score: 0.013
  41. A new mild hyperthermia device to treat vascular involvement in cancer surgery. Sci Rep. 2017 09 12; 7(1):11299.
    View in: PubMed
    Score: 0.013
  42. Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prev Res (Phila). 2017 Oct; 10(10):588-597.
    View in: PubMed
    Score: 0.012
  43. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. Oncotarget. 2017 Jul 04; 8(27):44447-44464.
    View in: PubMed
    Score: 0.012
  44. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. 2018 02; 32(2):343-352.
    View in: PubMed
    Score: 0.012
  45. Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer. Mol Cancer Res. 2017 08; 15(8):1017-1028.
    View in: PubMed
    Score: 0.012
  46. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. Oncogene. 2017 08 17; 36(33):4767-4777.
    View in: PubMed
    Score: 0.012
  47. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017 09; 31(9):1951-1961.
    View in: PubMed
    Score: 0.012
  48. Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. Autophagy. 2017 Mar 04; 13(3):506-521.
    View in: PubMed
    Score: 0.012
  49. TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway. Oncogene. 2017 04 27; 36(17):2377-2393.
    View in: PubMed
    Score: 0.012
  50. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017 03; 31(3):678-687.
    View in: PubMed
    Score: 0.012
  51. PPAR? agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity. Oncotarget. 2016 Sep 20; 7(38):60954-60970.
    View in: PubMed
    Score: 0.012
  52. Generation of an in?vitro 3D PDAC stroma rich spheroid model. Biomaterials. 2016 11; 108:129-42.
    View in: PubMed
    Score: 0.012
  53. ?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 2016 06 13; 29(6):874-888.
    View in: PubMed
    Score: 0.011
  54. MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma. J Invest Dermatol. 2016 09; 136(9):1920-1924.
    View in: PubMed
    Score: 0.011
  55. The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP. Neoplasia. 2016 06; 18(6):356-70.
    View in: PubMed
    Score: 0.011
  56. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2016 May 03; 7(18):25930-48.
    View in: PubMed
    Score: 0.011
  57. Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep. 2016 Mar 08; 14(9):2154-2165.
    View in: PubMed
    Score: 0.011
  58. Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma. Nucl Recept Signal. 2015; 13:e006.
    View in: PubMed
    Score: 0.011
  59. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett. 2016 Feb 28; 371(2):214-24.
    View in: PubMed
    Score: 0.011
  60. Single-Molecule Sequencing Reveals Estrogen-Regulated Clinically Relevant lncRNAs in Breast Cancer. Mol Endocrinol. 2015 Nov; 29(11):1634-45.
    View in: PubMed
    Score: 0.011
  61. Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus. Mol Endocrinol. 2015 Oct; 29(10):1426-39.
    View in: PubMed
    Score: 0.011
  62. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015 Sep 24; 126(13):1565-74.
    View in: PubMed
    Score: 0.011
  63. miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation. Mol Endocrinol. 2015 Aug; 29(8):1170-83.
    View in: PubMed
    Score: 0.011
  64. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. PLoS One. 2015; 10(5):e0127678.
    View in: PubMed
    Score: 0.011
  65. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma. Proc Natl Acad Sci U S A. 2015 Mar 17; 112(11):E1272-7.
    View in: PubMed
    Score: 0.010
  66. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature. 2015 Jan 29; 517(7536):626-30.
    View in: PubMed
    Score: 0.010
  67. Identification of p38? as a therapeutic target for the treatment of S?zary syndrome. J Invest Dermatol. 2015 Feb; 135(2):599-608.
    View in: PubMed
    Score: 0.010
  68. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
    View in: PubMed
    Score: 0.010
  69. Steroid receptor coactivator 1 is an integrator of glucose and NAD+/NADH homeostasis. Mol Endocrinol. 2014 Mar; 28(3):395-405.
    View in: PubMed
    Score: 0.010
  70. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013 Jul 01; 73(13):4134-46.
    View in: PubMed
    Score: 0.009
  71. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6997-7002.
    View in: PubMed
    Score: 0.009
  72. Long-range massively parallel mate pair sequencing detects distinct mutations and similar patterns of structural mutability in two breast cancer cell lines. Cancer Genet. 2011 Aug; 204(8):447-57.
    View in: PubMed
    Score: 0.008
  73. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res. 2011 Jun 01; 71(11):3841-51.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.